CJC-1295 (no DAC)vsHCG

CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.

When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.

The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.

Human Chorionic Gonadotropin is a glycoprotein hormone composed of two non-covalently linked subunits: an alpha subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique beta subunit (145 amino acids) that confers biological specificity. HCG's beta subunit shares approximately 85% amino acid homology with the LH beta subunit, allowing HCG to bind and activate the LH/CG receptor (LHCGR) on Leydig cells in the testes with equal or greater affinity than LH itself.

LHCGR is a Gs-coupled GPCR that activates adenylyl cyclase upon ligand binding, increasing intracellular cAMP. cAMP activates PKA, which phosphorylates the steroidogenic acute regulatory protein (StAR). Phosphorylated StAR transports cholesterol from the outer to the inner mitochondrial membrane — the rate-limiting step in steroid hormone synthesis. Inside the mitochondria, the cholesterol side-chain cleavage enzyme (CYP11A1) converts cholesterol to pregnenolone, which then undergoes a series of enzymatic conversions (through the delta-4 or delta-5 pathway) to produce testosterone. This entire steroidogenic cascade occurs within Leydig cells and produces intratesticular testosterone concentrations 50-100 times higher than serum levels — essential for spermatogenesis in the adjacent seminiferous tubules.

HCG's longer half-life compared to LH (24-36 hours vs 20 minutes) is due to its heavily glycosylated beta subunit, which reduces renal clearance. This extended duration makes it practical for intermittent injection protocols. In addition to stimulating testosterone, HCG activates aromatase (CYP19A1) in Leydig cells, converting some of the produced testosterone to estradiol — which is why HCG use can elevate estrogen levels, potentially causing gynecomastia and water retention. HCG also maintains Sertoli cell function (which supports spermatogenesis) through indirect paracrine signaling from testosterone-producing Leydig cells. The physical preservation of testicular volume during TRT is a direct result of maintained Leydig cell activity and seminiferous tubule function.